This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Fresenius Medical's (FMS) New HHD Device to Increase Portability
by Zacks Equity Research
Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.
NextGen (NXGN) Behavioral Health Suite to Address Mental Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to ease state reporting and enable the secure sharing of patient information across providers.
Thermo Fisher (TMO) Launches New Chromosomal Microarray
by Zacks Equity Research
Thermo Fisher's (TMO) CytoScan HD Accel array can save labs weeks or even months by accelerating the time it takes to get findings from cytogenetic research.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Up (Revised)
by Zacks Equity Research
Strength across businesses and geographies, driven by execution, innovation, and improved underlying fundamentals contributes to Medtronic (MDT) Q1 revenues.
Patterson Cos. (PDCO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Patterson Cos. (PDCO) closed the most recent trading day at $33.78, moving -0.65% from the previous trading session.
Here's Why You Should Invest in HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients
by Zacks Equity Research
Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI surgery.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS' (STE) successful integration of the recently-acquired business and raised guidance.
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Strength across businesses and geographies, driven by execution, innovation and improved underlying fundamentals, contributes to Medtronic's (MDT) Q1 revenues.
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by Invisalign portfolio expansion and raised guidance.
Is Patterson Companies (PDCO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Patterson Cos. (PDCO) and Abcam PLC Sponsored ADR (ABCM) have performed compared to their sector so far this year.
Reasons to Retain West Pharmaceutical (WST) Stock for Now
by Zacks Equity Research
West Pharmaceutical's (WST) strength in its proprietary products segment raises optimism about the stock.
Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS implant for durable pain relief and significant improvements in patient condition post-implantation.
Here's Why You Should Invest in Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are upbeat about Penumbra (PEN) on Strong uptake following the launch of Lightning Flash, which accelerated top-line growth.
What's in the Cards for Medtronic (MDT) in Q1 Earnings?
by Zacks Equity Research
Strength across all businesses is likely to drive Medtronic's (MDT) first-quarter performance.
McKesson (MCK) & Genpact Extend Tie Up to Improve Workflow
by Zacks Equity Research
McKesson's (MCK) latest partnership extension is likely to transform its finance operations for enhanced service and competitive growth.
TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant
by Zacks Equity Research
TransMedics' (TMDX) acquisition of Summit Aviation is likely to help establish TransMedics Aviation, the first integrated national provider of air logistics dedicated exclusively to organ transplantation.
Phibro's (PAHC) Sales Hurt by Rising Costs, FX Headwind
by Zacks Equity Research
Phibro (PAHC) input costs continue to be high as a result of sustained inflation.
Neogen (NEOG) Introduces New Genomic Data Management Tool
by Zacks Equity Research
Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) continued growth across the insured and self-insured medical, pharmacy, dental and behavioral health products and services.
Patterson Companies (PDCO) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) broad product line.
Thermo Fisher (TMO) Completes the CorEvitas Acquisition
by Zacks Equity Research
Thermo Fisher's (TMO) latest buyout is likely to deliver $0.03 in adjusted earnings per share in 2024 and be marginally accretive in 2023.
West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.